
Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) – Research analysts at HC Wainwright raised their FY2026 EPS estimates for shares of Avidity Biosciences in a research note issued to investors on Friday, November 13th. HC Wainwright analyst M. Kapoor now anticipates that the biotechnology company will post earnings per share of ($3.51) for the year, up from their prior estimate of ($5.61). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Avidity Biosciences’ current full-year earnings is ($4.45) per share. HC Wainwright also issued estimates for Avidity Biosciences’ Q4 2026 earnings at ($1.05) EPS, Q1 2027 earnings at ($1.12) EPS, Q2 2027 earnings at ($1.21) EPS, Q3 2027 earnings at ($1.30) EPS, Q4 2027 earnings at ($1.44) EPS and FY2027 earnings at ($5.07) EPS.
Several other equities research analysts also recently weighed in on the stock. Weiss Ratings raised shares of Avidity Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday. Roth Capital initiated coverage on Avidity Biosciences in a research report on Thursday, October 22nd. They issued a “buy” rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Avidity Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.
Get Our Latest Research Report on RNA
Avidity Biosciences Stock Down 14.4%
NASDAQ:RNA opened at $6.43 on Tuesday. The company’s 50 day moving average price is $8.49 and its 200-day moving average price is $17.92. Avidity Biosciences has a 52 week low of $6.36 and a 52 week high of $16.77. The stock has a market cap of $110.02 million and a price-to-earnings ratio of -2.99.
Avidity Biosciences (NASDAQ:RNA – Get Free Report) last issued its earnings results on Thursday, November 12th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.56. The firm had revenue of $15.32 million during the quarter, compared to analysts’ expectations of $15.00 million.
About Avidity Biosciences
Avidity Biosciences is a biotechnology company focused on developing RNA-based medicines for diseases that affect muscle. Its Antibody Oligonucleotide Conjugate (AOC) platform combines antibodies with oligonucleotides to help deliver RNA-targeting treatments into muscle cells. The company’s research and clinical pipeline has included programs for neuromuscular disorders such as myotonic dystrophy type 1 and Duchenne muscular dystrophy. Avidity was founded in 2012 and is based in San Diego, California.
Read More
- Five stocks we like better than Avidity Biosciences
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Avidity Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avidity Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
